Press

Revive Therapeautics

Revive Therapeutics Announces Results of Annual Shareholder Meeting

TORONTO, March 19, 2025 (GLOBE NEWSWIRE) —  Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce the voting results for its annual and special meeting of shareholders…

Clearmind

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Vancouver, Canada, March 19, 2025 — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has signed a non-binding Letter of Intent (LOI) with Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon”), a development stage…

Red Light Holland

Red Light Holland Appoints Michael Galloro to Board of Directors

Toronto, Ontario–(Newsfile Corp. – March 19, 2025) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to…

Psyence

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

New York, New York–(Newsfile Corp. – March 18, 2025) – Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence Biomed” or the “Company”) today announced that it has expanded and further strengthened its Scientific Advisory Board (SAB) with the appointment of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology. He is the Professor and…